Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls and deadlines has, of course, returned. To cope, yes, we are firing up the coffee kettle in the Pharmalot cafeteria and brewing a few cups of stimulation. Our choice today is gingerbread spice. As always, feel free to join us. Remember, no prescription is required, so no need to contend with rebates. Meanwhile, here is the latest menu of tidbits to get you going. We hope you have a smashing day, and do keep in touch. We appreciate suggestions, juicy tips, and feedback. …

AstraZeneca (AZN) reported that its Enhertu cancer drug significantly helped women suffering from a type of breast cancer, opening the door to a much larger potential patient group, Reuters notes. The company, which is working on the drug with Daiichi Sankyo, said that Enhertu prolonged the survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2. The improvement was “clinically meaningful.” Analysts have said a positive trial read-out could portend future use at an earlier stage of the disease with potentially hundreds of thousands of new eligible patients per year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment